TCG Lifesciences and CarnaBio enter into strategic alliance

TCG Lifesciences of India and Carna Biosciences of Japan have entered into a strategic alliance.

TCG Lifesciences of India and Carna Biosciences of Japan have entered into a strategic alliance to collaborate and provide jointly,high end drug discovery services focusing on kinase targets,to the global pharma and biotech companies.

CarnaBio and TCGLS possess complementary capabilities and,by virtue of this alliance,expect to jointly address the research and development needs of their existing and future customers by offering seamless services through the entire drug discovery and development value chain in selected therapeutic areas which target on kinases.

CarnaBios President & CEO Dr. Yoshino commented on the collaboration,With our expertise in kinase based discovery services including HTS,the broadest kinase profiling panel,and related services and TCGLS capabilities in integrated drug discovery and development offerings,we are sure that this alliance will enhance the reach and capabilities of both organizations and will result in high-end services and innovative solutions for the pharma and biotech industry,helping them to develop new drugs.

Commenting on this new alliance,Swapan Bhattacharya,Managing Director of TCGLS,said Our relationship with CarnaBio began by TCGLS providing chemistry services to support CarnaBios internal research programs and now has blossomed into a strategic relationship that hopes to deliver higher value addition to our respective customers by combining the unique capabilities and best practices of both organizations. Kinase based targets are in high demand today particularly for the discovery of novel therapeutics for cancer.